PE20142330A1 - Vacuna de peptido ch3 de ige - Google Patents

Vacuna de peptido ch3 de ige

Info

Publication number
PE20142330A1
PE20142330A1 PE2014000753A PE2014000753A PE20142330A1 PE 20142330 A1 PE20142330 A1 PE 20142330A1 PE 2014000753 A PE2014000753 A PE 2014000753A PE 2014000753 A PE2014000753 A PE 2014000753A PE 20142330 A1 PE20142330 A1 PE 20142330A1
Authority
PE
Peru
Prior art keywords
ige
formula
crimp
referred
peptide vaccine
Prior art date
Application number
PE2014000753A
Other languages
English (en)
Spanish (es)
Inventor
Alan Daniel Brown
Brian Robert Champion
Clare Christy
David Paul Gervais
Lyn Howard Jones
Anne Maria Kristina Kjerrstrom
David Cameron Pryde
Lee Richard Roberts
David Michael Wyatt
Original Assignee
Pfizer Vaccines Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42035836&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20142330(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Vaccines Llc filed Critical Pfizer Vaccines Llc
Publication of PE20142330A1 publication Critical patent/PE20142330A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PE2014000753A 2008-12-09 2009-12-04 Vacuna de peptido ch3 de ige PE20142330A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12098908P 2008-12-09 2008-12-09

Publications (1)

Publication Number Publication Date
PE20142330A1 true PE20142330A1 (es) 2015-01-14

Family

ID=42035836

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2014000753A PE20142330A1 (es) 2008-12-09 2009-12-04 Vacuna de peptido ch3 de ige
PE2011001186A PE20110891A1 (es) 2008-12-09 2009-12-04 Vacuna de peptido ch3 de ige

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2011001186A PE20110891A1 (es) 2008-12-09 2009-12-04 Vacuna de peptido ch3 de ige

Country Status (21)

Country Link
US (3) US8298547B2 (enExample)
EP (2) EP2865389A1 (enExample)
JP (4) JP5209800B2 (enExample)
KR (3) KR101644221B1 (enExample)
CN (1) CN102245198B (enExample)
AR (1) AR074505A1 (enExample)
AU (1) AU2009325950B2 (enExample)
BR (1) BRPI0922561A2 (enExample)
CA (1) CA2744754A1 (enExample)
CO (1) CO6561830A2 (enExample)
DK (1) DK2376108T3 (enExample)
ES (1) ES2622562T3 (enExample)
IL (1) IL213029A0 (enExample)
MX (2) MX2011006077A (enExample)
NZ (2) NZ592977A (enExample)
PE (2) PE20142330A1 (enExample)
RU (1) RU2495049C2 (enExample)
SG (2) SG10201400388QA (enExample)
TW (1) TWI387463B (enExample)
WO (1) WO2010067286A2 (enExample)
ZA (1) ZA201104072B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2594591B1 (en) * 2005-08-11 2018-06-06 Arpi Matossian-Rogers Tcr-v-beta related peptides for treatment and diagnosis of autoimmune disease
US8552165B2 (en) * 2008-12-09 2013-10-08 Heather Davis Immunostimulatory oligonucleotides
CA2745096C (en) 2008-12-09 2013-11-05 Coley Pharmaceutical Group, Inc. Immunostimulatory oligonucleotides
CA2800774A1 (en) 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
EP2471926A3 (en) 2010-12-30 2012-07-11 Intervet International BV Immunostimulatory oligodeoxynucleotides
EP2714907B1 (en) * 2011-05-26 2016-06-15 Intervet International B.V. Immunostimulatory oligodeoxynucleotides
CN107513533A (zh) * 2011-05-26 2017-12-26 英特维特国际股份有限公司 免疫刺激性寡脱氧核苷酸
US9956276B2 (en) 2012-01-19 2018-05-01 Duke University Vaccines against antigens involved in therapy resistance and methods of using same
US9187553B2 (en) * 2012-01-25 2015-11-17 Swey-Shen Chen Displaying native human IgE neutralizing FcepsilonRIa-contacting IgE B-cell epitopes by constraining super beta(b)-strands and cystine knots on thermostable protein scaffold
JP5918851B2 (ja) * 2012-06-18 2016-05-18 日本全薬工業株式会社 ＩｇＥペプチドワクチン
WO2016007499A1 (en) 2014-07-07 2016-01-14 Duke University Vaccines against an oncogenic isoform of her2 (erbb2) and methods of using the same
CA2954279C (en) 2014-07-07 2023-11-14 Duke University Vaccines against an oncogenic isoform of esr1 and methods of using the same
RU2021100991A (ru) 2014-07-10 2021-03-01 Аффирис Аг Вещества и способы для применения при предупреждении и/или лечении болезни гентингтона
EP3357507A4 (en) * 2015-09-30 2019-05-29 Shionogi & Co., Ltd NUCLEIC ACID DERIVATIVE WITH IMMUNOSTIMULATING EFFECT
KR101876620B1 (ko) * 2015-10-27 2018-07-09 대구한의대학교산학협력단 펩타이드 기반 분자결합자를 이용한 노로바이러스 검출칩 및 그 제작방법
CN108697779B (zh) 2016-01-07 2023-09-19 杜克大学 癌症疫苗和递送方法
JP7041923B2 (ja) 2016-03-03 2022-03-25 学校法人藤田学園 大豆アレルギーの抗原
US11224665B2 (en) 2016-10-05 2022-01-18 Duke University Mitochondrial antiviral signaling (MAVS) protein compositions and methods of using the same
US10487143B2 (en) 2016-10-05 2019-11-26 Duke University Vaccines against HER3 antigens and methods of using the same
SG11201908059YA (en) * 2017-03-29 2019-10-30 Shionogi & Co Nucleic acid derivative having immunostimulatory activity
JP7549148B2 (ja) * 2020-08-13 2024-09-10 ナイベック カンパニー リミテッド 細胞内の腫瘍誘発タンパク質をターゲットとする抗体又はその単一鎖可変断片と癌細胞透過性ペプチドの融合タンパク質及びその用途
EP4213874A1 (en) 2020-09-17 2023-07-26 Neovacs Immunogenic product comprising an ige fragment for treating ige-mediated inflammatory disorders
US20250205331A1 (en) * 2022-03-28 2025-06-26 The Regents Of The University Of California Novel plant virus and bacteriophage vaccines

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2055131B (en) 1978-09-29 1982-12-15 Energy Secretary Of State For Electrical power transmission in fluid wells
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
WO1983001451A1 (en) 1981-10-23 1983-04-28 Molecular Biosystems Inc Oligonucleotide therapeutic agent and methods of making same
US4722840A (en) 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
US5374426A (en) 1986-09-03 1994-12-20 University Of Saskatchewan Rotavirus nucleocapsid protein VP6 in vaccine compositions
JPS63225397A (ja) * 1986-10-03 1988-09-20 Dainippon Pharmaceut Co Ltd 抗アレルギー作用を有する新規ペプチド
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
NZ235315A (en) 1989-09-19 1991-09-25 Wellcome Found Chimaeric hepadnavirus core antigen proteins and their construction
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
US5258289A (en) * 1990-09-05 1993-11-02 Davis Claude G Method for the selecting of genes encoding catalytic antibodies
JPH06503821A (ja) 1990-12-20 1994-04-28 スミスクライン・ビーチャム・バイオロジカルス（ソシエテ・アノニム） Ｂ型肝炎表面抗原に基づくワクチン
SE9102808L (sv) * 1991-09-26 1993-03-27 Lars T Hellman Inst F Immunolo Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner
EP0761231B1 (en) 1992-06-25 2000-01-12 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine composition containing adjuvants
ES2162139T5 (es) 1993-03-23 2008-05-16 Smithkline Beecham Biologicals S.A. Composiciones de vacuna que contienen monofosforil-lipido a 3-o-desacilado.
DE4321946A1 (de) 1993-07-01 1995-01-12 Hoechst Ag Methylphosphonsäureester, Verfahren zu deren Herstellung und deren Verwendung
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5658738A (en) 1994-05-31 1997-08-19 Becton Dickinson And Company Bi-directional oligonucleotides that bind thrombin
EP0772619B2 (en) 1994-07-15 2010-12-08 The University of Iowa Research Foundation Immunomodulatory oligonucleotides
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
EP0817854A2 (en) 1995-03-31 1998-01-14 Wolf, Hans, Prof. Dr. Antigen presentation system based on retrovirus-like particles
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
EP0885244B2 (en) 1996-03-01 2008-04-16 Novartis AG Peptide immunogens for vaccination against and treatment of allergy
ID18046A (id) 1996-08-20 1998-02-19 Takeda Chemical Industries Ltd Senyawa siklik campuran, pembuatan dan penngunaannya.
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
ATE292980T1 (de) 1996-10-11 2005-04-15 Univ California Immunostimulierende oligonucleotidekonjugate
AUPO517897A0 (en) * 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
AU738513B2 (en) 1997-02-28 2001-09-20 University Of Iowa Research Foundation, The Use of nucleic acids containing unmethylated CpG dinucleotide in the treatment of LPS-associated disorders
EP1005368B1 (en) 1997-03-10 2009-09-02 Ottawa Hospital Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide in combination with alum as adjuvants
DE69838294T2 (de) 1997-05-20 2009-08-13 Ottawa Health Research Institute, Ottawa Verfahren zur Herstellung von Nukleinsäurekonstrukten
ATE432348T1 (de) 1997-06-06 2009-06-15 Univ California Inhibitoren von immunstimulatorischen dna sequenz aktivität
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9717953D0 (en) 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
DE69838992T2 (de) 1997-09-05 2008-12-24 Glaxosmithkline Biologicals S.A., Rixensart Öl-in-Wasser Emulsionen mit Saponinen
US6231864B1 (en) 1998-02-12 2001-05-15 Immune Complex Corporation Strategically modified hepatitis B core proteins and their derivatives
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
ES2284247T3 (es) 1998-04-03 2007-11-01 University Of Iowa Research Foundation Metodos y productos para estimular el sistema inmunitario usando oligonucleotidos y citoquinas inmunoterapeuticos.
US7393529B2 (en) * 1998-04-09 2008-07-01 Idexx Laboratories, Inc. Methods and compositions for inhibiting binding of IgE to a high affinity receptor
US6734287B1 (en) * 1998-04-09 2004-05-11 Idexx Laboratories, Inc. Specific binding proteins for treating canine allergy
ES2234180T3 (es) * 1998-04-09 2005-06-16 Idexx Laboratories, Inc. Proteinas de fijacion especifica para el tratamiento de la alergia canina.
WO1999052549A1 (en) 1998-04-09 1999-10-21 Smithkline Beecham Biologicals S.A. Adjuvant compositions
TWI227241B (en) * 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
ATE434440T1 (de) 1998-09-03 2009-07-15 Novartis Vaccines & Diagnostic Fgf-2 angiogenische wirksame einheitdosis und verfahren zu ihrer verwendung
DE59806475D1 (de) 1998-09-18 2003-01-09 Pentapharm Ag Basel Urokinase-inhibitoren
CZ301212B6 (cs) 1998-10-16 2009-12-09 Smithkline Beecham Biologicals S. A. Vakcinacní prostredek
AU770802B2 (en) 1998-10-21 2004-03-04 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Virus-like particles for the induction of autoantibodies
US6913749B2 (en) 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
ES2257879T3 (es) 1998-11-05 2006-08-01 Powderject Vaccines, Inc. Productos de recombinacion de acido nucleico para inmunizacion genetica.
ES2317711T3 (es) 1998-11-30 2009-04-16 Cytos Biotechnology Ag Presentacion molecular de alergenos, metodos de preparacion y uso.
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
EP1150710B1 (en) 1999-02-17 2010-04-21 Csl Limited Immunogenic complexes and methods relating thereto
US20030170229A1 (en) * 1999-02-25 2003-09-11 Smithkline Beecham Biologicals S.A. Vaccine
CZ20013081A3 (cs) 1999-02-25 2002-02-13 Smithkline Beecham Biologicals S. A. Epitopy a mimotopy získané z oblastí C-epsilon-2 nebo C-epsilon-4 IgE, jejich antagonisté a jejich terapeutické pouľití
EP1162999B1 (en) 1999-03-19 2006-11-29 Glaxosmithkline Biologicals S.A. Vaccine against Streptococcus pneumoniae
WO2000058365A1 (en) * 1999-03-30 2000-10-05 Idexx Laboratories, Inc. Specific binding proteins for treating canine allergy
TR200103018T2 (tr) 1999-04-19 2002-02-21 Beecham Biologicals S.A. Smithkline İmmünostimülatör oligonükleotid ve saponin içeren katkı bileşikleri.
JP2003509473A (ja) 1999-09-24 2003-03-11 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ワクチン
KR20020048942A (ko) 1999-09-24 2002-06-24 장 스테판느 폴리옥시에틸렌 알킬 에테르 또는 에스테르 및 하나이상의 비이온성 계면활성제를 포함하는 애쥬번트
JP2003510290A (ja) 1999-09-27 2003-03-18 コーリー ファーマシューティカル グループ，インコーポレイテッド 免疫刺激核酸誘導インターフェロンに関する方法
KR100808313B1 (ko) 2000-04-07 2008-02-27 유니버시티 오브 리즈 이노베이션즈 리미티드 비형 간염 코어 항원 융합 단백질
AU2001252458A1 (en) 2000-05-05 2001-11-20 Martin Bachmann Molecular antigen arrays and vaccines
US20040054139A1 (en) 2000-06-22 2004-03-18 Mark Page Modification of hepatitis b core antigen
EP1304947A1 (en) 2000-07-15 2003-05-02 Lighthouse Display International Limited Shelf edge display fittings
AUPQ912000A0 (en) 2000-07-31 2000-08-24 Crown In The Right Of The Queensland Department Of Health, The Improved virus like particles
US20030138769A1 (en) 2000-08-16 2003-07-24 Birkett Ashley J. Immunogenic HBc chimer particles having enhanced stability
EP1195161A3 (en) * 2000-08-30 2002-07-24 Pfizer Products Inc. Anti-IgE vaccines
GB0026334D0 (en) * 2000-10-27 2000-12-13 Smithkline Beecham Biolog Vaccine
US7320793B2 (en) 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
WO2003102165A2 (en) 2002-02-21 2003-12-11 Apovia, Inc. IMMUNOGENIC HBc CHIMER PARTICLES STABILIZED WITH AN N-TERMINAL CYSTEINE
EP1425040A2 (en) 2001-09-14 2004-06-09 Cytos Biotechnology AG In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
ATE447967T1 (de) 2001-09-14 2009-11-15 Cytos Biotechnology Ag Verpackung von immunstimulierendem cpg in virusähnlichen partikeln: herstellungsverfahren und verwendung
US8088388B2 (en) 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
US20040176283A1 (en) * 2002-04-01 2004-09-09 Robinson John A. Methods and compositions for the design of synthetic vaccines
GB0209878D0 (en) 2002-04-30 2002-06-05 Glaxosmithkline Biolog Sa Vaccine
CU22983A1 (es) * 2002-05-08 2004-09-09 Inst Finlay Composición vacunal contra las alergias y método para su obtención y empleo en el tratamiento de las mismas
RU2324704C2 (ru) 2002-07-17 2008-05-20 Цитос Байотекнолоджи Аг Молекулярные массивы антигенов
CN1838967B (zh) 2002-12-10 2010-05-26 洛伦蒂斯有限公司 稳定的免疫原性HBc嵌合体颗粒
JP5022028B2 (ja) * 2003-03-26 2012-09-12 サイトス・バイオテクノロジー・アクチェンゲゼルシャフト メラン−ａペプチドアナログ−ウイルス様粒子コンジュゲート
CN102702359A (zh) 2004-02-02 2012-10-03 泰勒公司 新的IgE表位的鉴别
JP2008506683A (ja) 2004-07-18 2008-03-06 コーリー ファーマシューティカル グループ， リミテッド 先天免疫応答を誘導するための方法および組成物
KR20100018029A (ko) 2004-07-18 2010-02-16 씨에스엘 리미티드 면역자극 복합체 및 향상된 인터페론-감마 반응을 유도하기 위한 올리고뉴클레오티드 제제
EP1736538A1 (en) 2005-06-21 2006-12-27 Cytos Biotechnology AG Process for the preparative purification of virus-like-particles (VLPs)
GB2443591B (en) * 2005-09-07 2010-04-28 Secr Defence Adjuvanted vaccine
EP1991678B2 (en) 2006-02-15 2020-07-15 Rechtsanwalt Thomas Beck Compositions and methods for oligonucleotide formulations
US20080166785A1 (en) 2006-08-16 2008-07-10 Monica Sala-Schaeffer Polynucleotides allowing the expression and secretion of recombinant HBsAg virus-like particles containing a foreign peptide, their production and use
US7867494B2 (en) 2007-04-02 2011-01-11 Amgen Fremont Inc. Anti-IgE antibodies
EP2158211B1 (en) * 2007-05-31 2016-08-10 Medigene AG Mutated structural protein of a parvovirus
US9501570B2 (en) 2014-07-14 2016-11-22 Verizon Patent And Licensing Inc. Dynamic routing system
US9719791B2 (en) 2014-12-10 2017-08-01 Mapquest, Inc. Computerized systems and methods for providing travel information and/or content to users
ES2893464T3 (es) 2016-06-23 2022-02-09 Ripples Ltd Procedimiento y aparato para imprimir en una bebida

Also Published As

Publication number Publication date
US8298547B2 (en) 2012-10-30
AR074505A1 (es) 2011-01-19
SG10201400388QA (en) 2014-05-29
PE20110891A1 (es) 2011-12-23
MX337723B (es) 2016-03-15
US20100158933A1 (en) 2010-06-24
TWI387463B (zh) 2013-03-01
JP2012511322A (ja) 2012-05-24
KR20130032390A (ko) 2013-04-01
KR101644221B1 (ko) 2016-07-29
DK2376108T3 (en) 2017-04-24
JP2014012009A (ja) 2014-01-23
CN102245198A (zh) 2011-11-16
US9216229B2 (en) 2015-12-22
KR20150056881A (ko) 2015-05-27
BRPI0922561A2 (pt) 2020-08-11
JP5209800B2 (ja) 2013-06-12
HK1163511A1 (zh) 2012-09-14
MX2011006077A (es) 2011-09-01
AU2009325950B2 (en) 2013-03-07
ZA201104072B (en) 2012-02-29
CN102245198B (zh) 2016-08-17
WO2010067286A3 (en) 2010-08-05
JP2012255006A (ja) 2012-12-27
AU2009325950A1 (en) 2010-06-17
ES2622562T3 (es) 2017-07-06
JP5964280B2 (ja) 2016-08-03
NZ604186A (en) 2014-07-25
EP2865389A1 (en) 2015-04-29
IL213029A0 (en) 2011-07-31
EP2376108B1 (en) 2017-02-22
US20140017239A1 (en) 2014-01-16
EP2376108A2 (en) 2011-10-19
JP2016164156A (ja) 2016-09-08
CA2744754A1 (en) 2010-06-17
KR101634058B1 (ko) 2016-06-27
TW201036632A (en) 2010-10-16
US8475801B2 (en) 2013-07-02
SG186611A1 (en) 2013-01-30
CO6561830A2 (es) 2012-11-15
RU2011121043A (ru) 2013-01-20
JP5367137B2 (ja) 2013-12-11
KR101413844B1 (ko) 2014-06-30
US20120294848A1 (en) 2012-11-22
KR20110094134A (ko) 2011-08-19
NZ592977A (en) 2013-01-25
WO2010067286A2 (en) 2010-06-17
RU2495049C2 (ru) 2013-10-10

Similar Documents

Publication Publication Date Title
PE20142330A1 (es) Vacuna de peptido ch3 de ige
EP2998315A3 (en) Newcastle disease virus vectored avian vaccines
WO2007011904A3 (en) Recombinant flu vaccines
PE20161560A1 (es) Vacuna de pcsk9
UA94717C2 (ru) Модифицированный вирус гриппа, предназначенный для мониторинга и повышения эффективности вакцины
DK1954308T3 (da) Stabiliseringsmidler til frysetørrede vacciner
PE20121393A1 (es) Analogo peptidico de oxintomodulina
CL2013003416A1 (es) Secuencia de peptidos quiméricos que comprende dsspl o dasph composiciones , usos y metodo para mejorar metabolismo de glucosa.
CO6480995A2 (es) Construcciones novedosas de proteina del virus de pailoma humano (hpv) y su uso en la prevencion de la enfermedad por el hpv
PE20081686A1 (es) Proteinas de fusion que comprenden un antigeno prame (dage)
AR081809A1 (es) Composiciones farmaceuticas que comprenden un polipeptido que comprende al menos un motivo cxxc y antigenos heterologos y usos de las mismas
WO2008124646A3 (en) Use of amyloid proteins as vaccine scaffolds
ECSP10010327A (es) Péptidos del fviii y su uso para hemofílicos tolerantes
WO2014150822A3 (en) Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use
MX2017003117A (es) Particula tipo virus de flavivirus.
JP2010532766A5 (enExample)
MX2021007285A (es) Particulas similares a virus del cmv modificadas por fusion.
NZ594268A (en) Grass peptides for vaccine
MX2022000778A (es) Proteina quimerica l1 del virus de papiloma humano.
ES2572367T3 (es) Péptidos con epítopos de la MELK y vacunas que los contienen
AR065765A1 (es) Composicion de vacuna para el tratamiento de enfermedades infecciosas respiratorias
AR083766A1 (es) Peptido inmunogenico
AR073967A1 (es) Peptido-epitope rab6kifl/kif20a y vacunas que contienen al mismo
CR11537A (es) Vacuna
BRPI0606614A2 (pt) peptìdeos para distribuição de vacinas na mucosa

Legal Events

Date Code Title Description
FD Application declared void or lapsed